Back to Sectors

IMCR

Immunocore Holdings plc
8 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBEARISH | 50% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/27/2026 | management changeNEUTRAL | 20% | 5/27/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

neutralMay 27

Board directors re-appointed despite notable opposition to specific members.

management change
40%
neutralMay 27

Successful completion of annual general meeting and auditor ratification.

regulatory action
20%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%
bullishMay 6

Achieved first positive operating income of $7.3 million.

earnings beat
70%
bullishMay 6

Revenue grew 13.6% YoY while SG&A expenses decreased by $2.3 million.

margin expansion
60%
bearishMay 6

R&D and SG&A expenses continue to consume over 90% of total revenue.

margin compression
50%

Filing History

8-KMay 27, 2026

The 8-K filing regarding the 2026 AGM presents a dichotomy between formal corporate success and underlying investor dissatisfaction. While the company successfully passed all ten resolutions, the disparity in vote totals between routine auditor appointments and executive pay reveals a growing tension regarding the company's financial stewardship. Investors are now weighing the benefit of a stable, experienced board against the risk of a looming proxy conflict driven by dissatisfaction over compensation and capital allocation.

10-QMay 6, 2026

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and persistent structural burn. The achievement of positive operating income is a psychological milestone for the company, yet the divergence between accounting profit and negative operating cash flow highlights the inherent volatility of the biotech transition. The surge in U.S. revenue provides a necessary cushion, but the high R&D-to-sales ratio indicates that the company is still heavily investing in its future at the expense of current liquidity. Investors are left to weigh the strength of the five-year survival data and the $845 million liquidity cushion against the reality of a negative cash flow trend and significant contractual obligations. The upcoming catalysts, including the PRAME-targeted trials and expansion into first-line melanoma, will likely determine if the current revenue growth is a sustainable trajectory or a temporary peak. The overall impact of the filing is one of cautious optimism tempered by a need for a clear path to free cash flow positivity.